Recent Advances in Targeted Delivery of Non-coding RNA-based Therapeutics for Atherosclerosis

Overview

Journal Mol Ther

Publisher Cell Press

Specialties Molecular Biology
Pharmacology

Date 2022 Aug 3

PMID 35918894

Authors

Xiaoxin Li

Hongzhao Qi

Weigang Cui

Zhibin Wang

Xiuxiu Fu

Tianxiang Li

Huibo Ma

Yanyan Yang

Tao Yu

Affiliations

Soon will be listed here.

Abstract

Cardiovascular disease (CVD) has overtaken infectious illnesses as the leading cause of mortality and disability worldwide. The pathology that underpins CVD is atherosclerosis, characterized by chronic inflammation caused by the accumulation of plaques in the arteries. As our knowledge about the microenvironment of blood vessel walls deepens, there is an opportunity to fine-tune treatments to target the mechanisms driving atherosclerosis more directly. The application of non-coding RNAs (ncRNAs) as biomarkers or intervention targets is increasing. Although these ncRNAs play an important role in driving atherosclerosis and vascular dysfunction, the cellular and extracellular environments pose a challenge for targeted transmission and therapeutic regulation of ncRNAs. Specificity, delivery, and tolerance have hampered the clinical translation of ncRNA-based therapeutics. Nanomedicine is an emerging field that uses nanotechnology for targeted drug delivery and advanced imaging. Recently, nanoscale carriers have shown promising results and have introduced new possibilities for nucleic acid targeted drug delivery, particularly for atherosclerosis. In this review, we discuss the latest developments in nanoparticles to aid ncRNA-based drug development, particularly miRNA, and we analyze the current challenges in ncRNA targeted delivery. In particular, we highlight the emergence of various kinds of nanotherapeutic approaches based on ncRNAs, which can improve treatment options for atherosclerosis.

Citing Articles

Extracellular Vesicles-in-Hydrogel (EViH) targeting pathophysiology for tissue repair.

Liu L, Liu W, Han Z, Shan Y, Xie Y, Wang J Bioact Mater. 2024; 44:283-318.

PMID: 39507371 PMC: 11539077. DOI: 10.1016/j.bioactmat.2024.10.017.

Autophagy-associated non-coding RNAs: Unraveling their impact on Parkinson's disease pathogenesis.

Hussain M, Moglad E, Afzal M, Sharma S, Gupta G, Sivaprasad G CNS Neurosci Ther. 2024; 30(5):e14763.

PMID: 38790149 PMC: 11126788. DOI: 10.1111/cns.14763.

Intracranial aneurysm circulating exosome-derived LncRNA ATP1A1-AS1 promotes smooth muscle cells phenotype switching and apoptosis.

Wang C, Li H, Zhou H, Xu Y, Li S, Zhu M Aging (Albany NY). 2024; 16(9):8320-8335.

PMID: 38728254 PMC: 11132007. DOI: 10.18632/aging.205821.

BioDeepfuse: a hybrid deep learning approach with integrated feature extraction techniques for enhanced non-coding RNA classification.

Avila Santos A, de Almeida B, Bonidia R, Stadler P, Stefanic P, Mandic-Mulec I RNA Biol. 2024; 21(1):1-12.

PMID: 38528797 PMC: 10968306. DOI: 10.1080/15476286.2024.2329451.

The role and medical prospects of long non-coding RNAs in cardiovascular disease.

Kim N, Chung W, Cho J Heart Fail Rev. 2023; 28(6):1437-1453.

PMID: 37796408 PMC: 10575999. DOI: 10.1007/s10741-023-10342-1.

References

Cremer S, Michalik K, Fischer A, Pfisterer L, Jae N, Winter C . Hematopoietic Deficiency of the Long Noncoding RNA MALAT1 Promotes Atherosclerosis and Plaque Inflammation. Circulation. 2018; 139(10):1320-1334. DOI: 10.1161/CIRCULATIONAHA.117.029015. View

Hong D, Kang Y, Borad M, Sachdev J, Ejadi S, Lim H . Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br J Cancer. 2020; 122(11):1630-1637. PMC: 7251107. DOI: 10.1038/s41416-020-0802-1. View

Crooke S, Vickers T, Liang X . Phosphorothioate modified oligonucleotide-protein interactions. Nucleic Acids Res. 2020; 48(10):5235-5253. PMC: 7261153. DOI: 10.1093/nar/gkaa299. View

Chen X, Mangala L, Rodriguez-Aguayo C, Kong X, Lopez-Berestein G, Sood A . RNA interference-based therapy and its delivery systems. Cancer Metastasis Rev. 2017; 37(1):107-124. PMC: 5898634. DOI: 10.1007/s10555-017-9717-6. View

Allahverdian S, Chaabane C, Boukais K, Francis G, Bochaton-Piallat M . Smooth muscle cell fate and plasticity in atherosclerosis. Cardiovasc Res. 2018; 114(4):540-550. PMC: 5852505. DOI: 10.1093/cvr/cvy022. View

Xu H, Liao C, Liang S, Ye B . A Novel Peptide-Equipped Exosomes Platform for Delivery of Antisense Oligonucleotides. ACS Appl Mater Interfaces. 2021; 13(9):10760-10767. DOI: 10.1021/acsami.1c00016. View

Turner E, Erwin M, Atigh M, Christians U, Saul J, Yazdani S . and Assessment of Keratose as a Novel Excipient of Paclitaxel Coated Balloons. Front Pharmacol. 2018; 9:808. PMC: 6078047. DOI: 10.3389/fphar.2018.00808. View

Robbins M, Judge A, Liang L, McClintock K, Yaworski E, MacLachlan I . 2'-O-methyl-modified RNAs act as TLR7 antagonists. Mol Ther. 2007; 15(9):1663-9. DOI: 10.1038/sj.mt.6300240. View

Gomez I, Ward B, Souilhol C, Recarti C, Ariaans M, Johnston J . Neutrophil microvesicles drive atherosclerosis by delivering miR-155 to atheroprone endothelium. Nat Commun. 2020; 11(1):214. PMC: 6954269. DOI: 10.1038/s41467-019-14043-y. View

10.

Lobatto M, Fuster V, Fayad Z, Mulder W . Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nat Rev Drug Discov. 2011; 10(11):835-52. PMC: 3623275. DOI: 10.1038/nrd3578. View

11.

Xu Y, Xu Y, Zhu Y, Sun H, Juguilon C, Li F . Macrophage miR-34a Is a Key Regulator of Cholesterol Efflux and Atherosclerosis. Mol Ther. 2019; 28(1):202-216. PMC: 6952168. DOI: 10.1016/j.ymthe.2019.09.008. View

12.

Lin Y, Wu J, Gu W, Huang Y, Tong Z, Huang L . Exosome-Liposome Hybrid Nanoparticles Deliver CRISPR/Cas9 System in MSCs. Adv Sci (Weinh). 2018; 5(4):1700611. PMC: 5908366. DOI: 10.1002/advs.201700611. View

13.

McCarthy J, Korngold E, Weissleder R, Jaffer F . A light-activated theranostic nanoagent for targeted macrophage ablation in inflammatory atherosclerosis. Small. 2010; 6(18):2041-9. PMC: 3018665. DOI: 10.1002/smll.201000596. View

14.

Khvorova A, Watts J . The chemical evolution of oligonucleotide therapies of clinical utility. Nat Biotechnol. 2017; 35(3):238-248. PMC: 5517098. DOI: 10.1038/nbt.3765. View

15.

Jin F, Yang L, Wang W, Yuan N, Zhan S, Yang P . A novel class of tsRNA signatures as biomarkers for diagnosis and prognosis of pancreatic cancer. Mol Cancer. 2021; 20(1):95. PMC: 8285832. DOI: 10.1186/s12943-021-01389-5. View

16.

Huang H, Barua S, Sharma G, Dey S, Rege K . Inorganic nanoparticles for cancer imaging and therapy. J Control Release. 2011; 155(3):344-57. DOI: 10.1016/j.jconrel.2011.06.004. View

17.

Wang R, Ding Y, Gao W, Pei Y, Yang J, Zhao Y . Serum microRNA-204 levels are associated with long-term cardiovascular disease risk based on the Framingham risk score in patients with type 2 diabetes: results from an observational study. J Geriatr Cardiol. 2020; 17(6):330-337. PMC: 7338935. DOI: 10.11909/j.issn.1671-5411.2020.06.006. View

18.

Wilson J . Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency. Mol Genet Metab. 2009; 96(4):151-7. DOI: 10.1016/j.ymgme.2008.12.016. View

19.

Duivenvoorden R, Tang J, Cormode D, Mieszawska A, Izquierdo-Garcia D, Ozcan C . A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation. Nat Commun. 2014; 5:3065. PMC: 4001802. DOI: 10.1038/ncomms4065. View

20.

Huang W, Wei P, Lin R, Huang F . Protective Effects of Microrna-22 Against Endothelial Cell Injury by Targeting NLRP3 Through Suppression of the Inflammasome Signaling Pathway in a Rat Model of Coronary Heart Disease. Cell Physiol Biochem. 2017; 43(4):1346-1358. DOI: 10.1159/000481846. View